Biofarm's EBIT per Share for the
three
months ended in Mar. 2026 was lei0.04.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was lei0.12.
During the past 12 months, the average EBIT per Share Growth Rate of Biofarm was 13.80% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 9.80% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 8.10% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 11.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Biofarm's EBIT per Share or its related term are showing as below:
LTS:0HTH'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -6.3 Med: 10.3 Max: 52.4
Current: 9.8
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Biofarm was 52.40% per year. The lowest was -6.30% per year. And the median was 10.30% per year.
LTS:0HTH's 3-Year EBIT Growth Rate is ranked better than 52.96% of 810
companies
in the Drug Manufacturers industry
Industry Median: 7.5
vs LTS:0HTH: 9.80
Biofarm's EBIT for the
three
months ended in Mar. 2026 was lei38.4 Mil.
Biofarm (LTS:0HTH) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Biofarm EBIT per Share Related Terms
Biofarm EBIT per Share Historical Data
* Premium members only.
The historical data trend for Biofarm's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was lei0.12
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biofarm (LTS:0HTH) has a EBIT per Share of lei0.12 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Biofarm and its competitors. According to the industry distribution chart, Biofarm ranks #381 out of 810 companies in the Drug Manufacturers industry, placing it in the top 47%.
Is Biofarm's EBIT per Share too high?
Biofarm's current EBIT per Share is lei0.12. Based on the distribution chart, Biofarm ranks #381 out of 810 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Biofarm has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Biofarm's EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Biofarm ranks #381 out of 810 companies for EBIT per Share. This puts Biofarm in the upper half of its industry. The industry median EBIT per Share is 7.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.50, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Biofarm and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biofarm's current EBIT per Share is lei0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofarm stock overvalued right now?
Biofarm (LTS:0HTH) has a current EBIT per Share of lei0.12. The stock's GF Value™ is lei0.15, compared to a current price of lei0.24 — trading 58% above its estimated fair value. The current EBIT per Share is lei0.12. Biofarm's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Biofarm (LTS:0HTH), the current EBIT per Share is lei0.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biofarm (LTS:0HTH) Overvalued in 2026?
Based on GuruFocus' analysis, Biofarm stock appears to be overvalued.
The current stock price of lei0.24 is trading 58% above its estimated GF Value™ of lei0.15.
Key valuation signals for LTS:0HTH:
EBIT per Share: lei0.12
GF Value™: lei0.15 vs. price of lei0.24 (58% above fair value)
No single metric tells the full story. See the LTS:0HTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biofarm SA is a company engaged in production and marketing in the pharmaceutical sector. It is involved in the manufacture and wholesale of over-the-counter drugs, prescription medications, and dietary supplements. The firm's product portfolio includes pharmaceutical preparations for the digestive system, musculoskeletal system, immune stimulation, respiratory system, cold & flu symptoms, and venous circulation improvement, as well as multivitamins, antioxidants, antiseptics, disinfectants, and cosmetics, among others. Some of its brands are Triferment, Colebil, Cavit, Anghirol, Clorocalcin, and Bixtonim. Additionally, the company offers services, such as investment in research, promotion, and packaging.
69GF Score
Get the complete analysis for LTS:0HTH
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HTH has been successfully added to your 
